SEC Tracker
Get the app

Janux Therapeutics JANX

Janux Therapeutics reports Q3 2026 financial results

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Cash and cash equivalents: $945.7 million as of Sept 30, 2026
  2. Net loss: $21.6 million for Q3 2026
  3. Research and development expenses: $30.6 million for Q3 2026
  4. First patient dosed in JANX013 Phase 1 study

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Janux Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Spyre Therapeutics SYRE public float $1.1B, Jun 30, 2025
  2. Schrodinger SDGR public float $1.1B, Jun 30, 2025
  3. Mannkind MNKD public float $1.1B, Jun 30, 2025
  4. Novavax NVAX public float $1.0B, Jun 30, 2025
  5. Harrow HROW public float $1.0B, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.